Mucinous borderline ovarian tumors withBRAF(V600E)mutation may have low risk for progression to invasive carcinomas

Purpose Mucinous ovarian carcinomas (MOCs) are relatively rare. It has been proposed that a subset of mucinous cystadenomas (MCAs) may progress to mucinous borderline tumors (MBTs), and then to MOCs.KRASis the predominantly mutated gene in MOC; however, other associated mutations and the mechanism underlying carcinogenesis in MOC remain unclear. Here, we assessed molecular genetic alterations in mucinous ovarian tumors and constructed mutation profiles. Methods Using the Sanger sequencing method, we assessed genetic mutations (KRAS,BRAF,TP53, andPIK3CA) in 16 cases of MOC, 10 cases of MBT, and 12 cases of MCA. Results Among MOC cases, the prevalence of G12D and G13DKRASmutations was 43.8% (7/16). No MOC cases showed V600EBRAFandTP53mutations. Among MBT cases, the prevalence of G12DKRASmutation was 20.0% (2/10), those ofTP53andPIK3CAmutations were nil, and that of V600EBRAFmutation was 40% (4/10). None of the genetic mutations assessed were detected among MCA cases. Conclusion These results suggest that MBT with V600EBRAFmutation may rarely progress to MOC, while MBT with G12D or G13DKRASmutation may more commonly progress to MOC.